RDHL - RedHill Biopharma Ltd.

1.03
0.183   17.806%

Share volume: 264,407
Last Updated: 04-23-2026
Pharmaceutical Products/Pharmaceutical Preparations: 3.16%

PREVIOUS CLOSE
CHG
CHG%
$0.85
0.18
0.22%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
15%
Profitability 15%
Dept financing 11%
Liquidity 75%
Performance 0%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
30.30%
1 Month
15.74%
3 Months
-21.37%
6 Months
-37.20%
1 Year
-55.60%
2 Year
145.30%
Key data
Stock price
$1.03
P/E Ratio 
0.00
DAY RANGE
$0.82 - $1.06
EPS 
-$1.53
52 WEEK RANGE
$0.71 - $3.31
52 WEEK CHANGE
-$57.26
MARKET CAP 
10.835 M
YIELD 
N/A
SHARES OUTSTANDING 
1.275 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
08-28-2025
BETA 
1.02
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$59,099
AVERAGE 30 VOLUME 
$38,941
Company detail
CEO: Dror Ben-Asher
Region: US
Website: redhillbio.com
Employees: 210
IPO year: 2013
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

RedHill Biopharma Ltd. primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections.

Recent news